Ira C. Spector

Ira C. Spector serves as the CEO and Co-Founder of SFA Therapeutics, a company focused on developing therapies for autoimmune diseases using a novel immuno-modulation platform. Under his leadership, the company announced positive results from the first cohort of their Phase 1b clinical trial of SFA-002 in treating mild-to-moderate chronic plaque psoriasis. This trial is an open-label, prospective study that has demonstrated the drug’s safety and high efficacy, with no related adverse events or toxicities observed. Dr. Daniel Sauder, a key figure in the study, highlighted SFA-002 as an incredibly safe oral drug. The second cohort of this trial is currently underway, with results expected by the end of 2023. Spector has also contributed to scientific literature, authoring an article on the role of short-chain fatty acids (SCFAs) in cancer pathogenesis, which discusses how SCFAs may prevent tumor development by blocking cancer stem cell proliferation and targeting mutated genes and pathways. SFA Therapeutics is advancing a portfolio of clinical and pre-clinical assets targeting multiple inflammatory diseases, with SFA-002 being the lead asset.